Top ▲


Disease ID:1189
Associated with:0 target
1 immuno-relevant ligand
bronchial disease
A lower respiratory tract disease that affects the airways leading into the lungs; caused by inflammation of the bronchi and bronchioles, infection, or blockage.
Database Links
Disease Ontology: DOID:1176


No target related data available for Bronchospasm


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Used to treat bronchospasm due to any cause.
Clinical Use: Highly selective β2-adrenoceptor agonist used in the treatment of COPD and asthma.
In April 2015, the FDA expanded approval to include treatment or prevention of bronchospasm in patients with reversible obstructive airway disease and for the treatment of exercise-induced bronchospasm (EIB).
A first-in-class, fixed-dose combination asthma rescue medication (delivered by a pressurised metered-dose inhaler) containing salbutamol/albuterol and (an anti-inflammatory inhaled corticosteroid), Airsupra®, was approved by the FDA in 2023. | View clinical data